Cargando…
Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used off-label for the treatment of many other malignancies. To comprehensively evaluate the efficacy of apatinib as a targeted...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525889/ https://www.ncbi.nlm.nih.gov/pubmed/34676173 http://dx.doi.org/10.3389/fonc.2021.749083 |